New cancer clinical trial: Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer

Published on: January 29, 2018 at 12:00PM
Conditions:   Glioblastoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancer
Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
http://ift.tt/2BCy3oU